Novartis circles back with new terms for a stem cell biotech buyout–report – FierceBiotech
Globes |
Novartis circles back with new terms for a stem cell biotech buyout–report
FierceBiotech Novartis' on-again, off-again deal to buy out Israeli stem cell therapy developer Gamida Cell is reportedly back on again–though the pharma giant has apparently renegotiated the old $600 million pact to include a smaller upfront buy-in and one of its … Novartis To Invest In Gamida Cell Before Acquistion Novartis to Invest Heavily in Gamida Cell |
